-+ 0.00%
-+ 0.00%
-+ 0.00%

MiNK Therapeutics Reports Preclinical Data Supporting AgenT-797 Combination in Colorectal Cancer

PUBT·11/06/2026 14:49:18
Listen to the news
MiNK Therapeutics Reports Preclinical Data Supporting AgenT-797 Combination in Colorectal Cancer
  • MiNK Therapeutics announced preclinical iNKT cell therapy findings scheduled for presentation at SITC on Nov. 6-7, 2026.
  • AgenT-797 enabled tumor-cell killing with botensilimab and balstilimab in a colorectal cancer liver-metastasis model resistant to the antibody combination alone.
  • The findings support an ongoing Phase 2 combination trial in previously treated microsatellite-stable colorectal cancer with liver metastases.
  • Both agenT-797 and MiNK-215 killed senescent breast cancer cells; MiNK-215 also targeted supporting fibroblasts, though senescent lung fibroblasts resisted both therapies.
  • AgenT-797 is also advancing in a randomized, placebo-controlled Phase 2 trial in acute hypoxemic respiratory failure, including ARDS.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mink Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611060948PRIMZONEFULLFEED9872214) on November 06, 2026, and is solely responsible for the information contained therein.